[go: up one dir, main page]

FR3053252B1 - Produit, ou agent actif, ou composition pour le soin des seins en periode pre-mensuelle ou menstruelle ou pour le soin de la symptomatologie des mastodynies - Google Patents

Produit, ou agent actif, ou composition pour le soin des seins en periode pre-mensuelle ou menstruelle ou pour le soin de la symptomatologie des mastodynies Download PDF

Info

Publication number
FR3053252B1
FR3053252B1 FR1656119A FR1656119A FR3053252B1 FR 3053252 B1 FR3053252 B1 FR 3053252B1 FR 1656119 A FR1656119 A FR 1656119A FR 1656119 A FR1656119 A FR 1656119A FR 3053252 B1 FR3053252 B1 FR 3053252B1
Authority
FR
France
Prior art keywords
care
mastodynia
symptomatology
product
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1656119A
Other languages
English (en)
Other versions
FR3053252A1 (fr
Inventor
Stephane Desjonqueres
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LABORATOIRES CARILENE, FR
Original Assignee
Laboratoires Carilene
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Carilene filed Critical Laboratoires Carilene
Priority to FR1656119A priority Critical patent/FR3053252B1/fr
Priority to US15/631,188 priority patent/US20180002281A1/en
Priority to ES201730858A priority patent/ES2657828B2/es
Priority to DE102017114413.7A priority patent/DE102017114413A1/de
Priority to GB1710439.9A priority patent/GB2556959A/en
Publication of FR3053252A1 publication Critical patent/FR3053252A1/fr
Application granted granted Critical
Publication of FR3053252B1 publication Critical patent/FR3053252B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C409/00—Peroxy compounds
    • C07C409/02—Peroxy compounds the —O—O— group being bound between a carbon atom, not further substituted by oxygen atoms, and hydrogen, i.e. hydroperoxides
    • C07C409/04—Peroxy compounds the —O—O— group being bound between a carbon atom, not further substituted by oxygen atoms, and hydrogen, i.e. hydroperoxides the carbon atom being acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/38—Percompounds, e.g. peracids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G75/00—Macromolecular compounds obtained by reactions forming a linkage containing sulfur with or without nitrogen, oxygen, or carbon in the main chain of the macromolecule
    • C08G75/24—Polysulfonates
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/006—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by oxidation
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/04—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils
    • C11C3/06—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils with glycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un produit, ou agent actif, ou une composition. Ce produit, agent actif ou composition consiste essentiellement en des lipides peroxydés, par exemple des Triesters de Glycérol perOxydés (en abrégé TGO) ou comprenant des lipides peroxydés, par exemple des Triesters de Glycérol perOxydés (en abrégé TGO), en particulier sous forme d'une huile végétale peroxydée, pour le soin ou le traitement des seins lors de phases prémenstruelles ou menstruelles et aussi pour le soin ou le traitement de la symptomatologie des mastodynies. L'invention permet la mise en œuvre d'une méthode de soin ou de traitement des seins lors de phases prémenstruelles ou menstruelles et aussi le soin ou le traitement de la symptomatologie des mastodynies.
FR1656119A 2016-06-29 2016-06-29 Produit, ou agent actif, ou composition pour le soin des seins en periode pre-mensuelle ou menstruelle ou pour le soin de la symptomatologie des mastodynies Active FR3053252B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR1656119A FR3053252B1 (fr) 2016-06-29 2016-06-29 Produit, ou agent actif, ou composition pour le soin des seins en periode pre-mensuelle ou menstruelle ou pour le soin de la symptomatologie des mastodynies
US15/631,188 US20180002281A1 (en) 2016-06-29 2017-06-23 Product, or active agent, or composition for the care of the breasts in a premenstrual or menstrual period or for the care of the symptomatology of mastodynia
ES201730858A ES2657828B2 (es) 2016-06-29 2017-06-28 Producto, o agente activo, o composicion para el cuidado de los senos en periodo pre-menstrual o menstrual o para el cuidado de la sintomatologia de las mastodinias
DE102017114413.7A DE102017114413A1 (de) 2016-06-29 2017-06-28 Produkt oder Wirkstoff oder Zusammensetzung zur Pflege der Brüste in der Zeit vor oder während der Menstruation oder zur Pflege der Symptomatologie von Mastodynien
GB1710439.9A GB2556959A (en) 2016-06-29 2017-06-29 Product, or active agent, or composition for the care of the breasts in a premenstrual or menstrual period or for the care of menstrual period or for the care

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1656119A FR3053252B1 (fr) 2016-06-29 2016-06-29 Produit, ou agent actif, ou composition pour le soin des seins en periode pre-mensuelle ou menstruelle ou pour le soin de la symptomatologie des mastodynies
FR1656119 2016-06-29

Publications (2)

Publication Number Publication Date
FR3053252A1 FR3053252A1 (fr) 2018-01-05
FR3053252B1 true FR3053252B1 (fr) 2020-04-24

Family

ID=56943727

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1656119A Active FR3053252B1 (fr) 2016-06-29 2016-06-29 Produit, ou agent actif, ou composition pour le soin des seins en periode pre-mensuelle ou menstruelle ou pour le soin de la symptomatologie des mastodynies

Country Status (5)

Country Link
US (1) US20180002281A1 (fr)
DE (1) DE102017114413A1 (fr)
ES (1) ES2657828B2 (fr)
FR (1) FR3053252B1 (fr)
GB (1) GB2556959A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210220423A1 (en) * 2021-04-06 2021-07-22 Earl Marek Pain reliever composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ280017A (en) * 1994-09-21 1997-06-24 Scotia Holdings Plc Use of n-6 or n-3 series essential fatty acid (efa), and optionally an oestrogen, to make a medicament to treat or prevent hormone replacement therapy (hrt) associated breast pain in peri- or postmenopausal women; medicaments containing the efa and estrogen.
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
FR2793410B1 (fr) * 1999-05-12 2004-10-29 Carilene Lab Utilisation de lipides peroxydes comme agents destines a prevenir et/ou a traiter les effets irritants d'un principe actif
FR2797586B1 (fr) * 1999-08-16 2001-11-09 Stephane Desjonqueres Utilisation de lipides peroxydes comme agents destines a former un film lipidique sur la peau
US20040081672A1 (en) * 2002-10-25 2004-04-29 Gupta Shyam K. Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging
FR2848852B1 (fr) * 2002-12-23 2007-03-16 Carilene Lab Composition huileuse a base de lipides peroxydes utilisable dans le traitement de la xerostomie
US20090130048A1 (en) * 2007-11-19 2009-05-21 Oronsky Bryan Todd Topical Composition for Treating Pain
FR2929516A1 (fr) * 2008-04-03 2009-10-09 Carilene Lab Composition dermatologique utilisable notamment pour le soin et la prevention des escarres
AU2009259972B2 (en) * 2008-06-19 2015-01-22 Lina Kennedy Product and composition for alleviating post-menstrual symptoms comprising Carapa procera and Calotropis procera
FR2947178B1 (fr) * 2009-06-29 2012-07-06 Effik Composition pharmaceutique a base de progesterone micronisee et ses utilisations
FR2954701B1 (fr) * 2009-12-24 2012-02-03 Carilene Lab Compositions dermatologiques contenant une association de lipides peroxydes et de zinc et leurs utilisations notamment dans le traitement de l'herpes
US20130345316A1 (en) * 2012-06-21 2013-12-26 L'oreal Water-releasing cosmetic composition

Also Published As

Publication number Publication date
ES2657828R1 (es) 2018-05-17
GB2556959A (en) 2018-06-13
ES2657828B2 (es) 2019-03-13
US20180002281A1 (en) 2018-01-04
ES2657828A2 (es) 2018-03-07
FR3053252A1 (fr) 2018-01-05
DE102017114413A1 (de) 2018-01-04
GB201710439D0 (en) 2017-08-16

Similar Documents

Publication Publication Date Title
MX382665B (es) 1,2,4-triazolonas 2,4,5-trisustituidas.
PH12021550931A1 (en) New anthelmintic compounds
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MA41060A (fr) Compositions comprenant des souches bactériennes
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
MA40754B1 (fr) Compositions comprenant des souches bactériennes
EP4374851A3 (fr) Composition ophtalmique pour le traitement d'une maladie de l' il sec
NZ748694A (en) Methods for making ultrasound contrast agents
EP3479831A4 (fr) Composition comprenant un exosome dérivé de cellules souches traitées par la thrombine pour le traitement d'une plaie de la peau
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
MX2019006291A (es) Composiciones de lactato de calcio y metodos de uso.
WO2016137164A3 (fr) Composition comprenant des vésicules extracellulaires dérivées de bactéries de bacillus sp. pour le traitement de maladies associées à la grossesse
NZ755442A (en) Topical cyclosporine-containing formulations and uses thereof
JOP20190262A1 (ar) مثبطات بيرازول magl
PH12020551796A1 (en) Branched fatty acids and esters thereof
EP3443966A4 (fr) Composition pour le traitement d'une maladie pulmonaire chronique, comprenant un exosome dérivé de cellules souches traitées par la thrombine
MX2021005248A (es) Anticuerpos contra cd73 activadores de células b.
EP3808791A4 (fr) Ester de phosphate de perfluoropolyéther, son procédé de production, et agent de traitement de surface le contenant en tant que principe actif
MX2020007462A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
EA201790699A1 (ru) Стабилизированные производные адреномедуллина и их применение
FR3053252B1 (fr) Produit, ou agent actif, ou composition pour le soin des seins en periode pre-mensuelle ou menstruelle ou pour le soin de la symptomatologie des mastodynies
FR3060307B1 (fr) Composition cosmetique comprenant des corps gras solides et un polymere gelifiant
EP4403219A3 (fr) Formulation stérile comprenant un oligonucléotide phosphorothioate stable
MX2019008782A (es) Composicion sinergica para el mantenimiento del equilibrio saludable de la microflora.
JOP20220136A1 (ar) صياغات تشتمل على معدن و/أو فيتامين وبولي سكاريد، تركيبات منها واستخدامها في المعدن و/أو الفيتامين المُكمل المذكور

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180105

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

TP Transmission of property

Owner name: LABORATOIRES CARILENE, FR

Effective date: 20240201

PLFP Fee payment

Year of fee payment: 9